Chen-Kan Tseng
Overview
Explore the profile of Chen-Kan Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee H, Huang B, Tseng C, Pai P, Hung T, Chao Y, et al.
Support Care Cancer
. 2024 Nov;
32(12):825.
PMID: 39589524
Purpose: During and after treatment, esophageal cancer (EC) patients experience changes in body mass index (BMI), performance status, nutrition status, symptom distress, and physical fitness. This study aims to evaluate...
2.
Ng C, Chiu C, Yeh C, Chang Y, Hou M, Tseng C, et al.
Ann Surg Oncol
. 2024 Jun;
31(10):6652-6661.
PMID: 38926213
Background: The prognosis for patients with esophageal cancer who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery has shown improvement in recent years. We sought to identify the critical factors contributing...
3.
Chen K, Huang C, Pai P, Yang W, Tseng C, Tsai H, et al.
J Neurooncol
. 2024 Apr;
167(2):371.
PMID: 38598089
No abstract available.
4.
Chen K, Huang C, Pai P, Yang W, Tseng C, Tsai H, et al.
J Neurooncol
. 2023 Dec;
165(3):535-545.
PMID: 38060066
Introduction: Blood-brain barrier (BBB) remains to be the major obstacle to conquer in treating patients with malignant brain tumors. Radiation therapy (RT), despite being the mainstay adjuvant modality regardless of...
5.
Yap W, Shih M, Chang Y, Lin C, Huang S, Tsai T, et al.
Biomedicines
. 2022 Nov;
10(11).
PMID: 36428557
Background: The prognosis of patients with resected esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy is particularly poor in those who were staged as ypT3/T4 and/or ypN+. This study investigated whether...
6.
Hsueh W, Hsueh S, Yeh K, Hung Y, Ho M, Lin S, et al.
In Vivo
. 2022 Sep;
36(5):2400-2408.
PMID: 36099141
Background/aim: Neoadjuvant concurrent chemoradiotherapy (CCRT) for esophageal cancer is often overwhelming due to its toxic effects. This study aimed to establish a prognostic indicator based on pretreatment albumin and neutrophil-to-lymphocyte...
7.
Lin S, Chuang C, Huang Y, Pai P, Lee C, Wei K, et al.
Appl Neuropsychol Adult
. 2022 Mar;
31(4):606-615.
PMID: 35343323
Infiltrative non-GBM gliomas are common primary intracranial malignancies, and postoperative adjuvant radiotherapy is recommended for most adult patients diagnosed with this disease to enhance local control and prolong intracranial progression-free...
8.
Ye X, Guo D, Tseng C, Ge J, Hung T, Pai P, et al.
Front Oncol
. 2022 Feb;
11:785788.
PMID: 35141147
Background: The current clinical workflow for esophageal gross tumor volume (GTV) contouring relies on manual delineation with high labor costs and inter-user variability. Purpose: To validate the clinical applicability of...
9.
Wei K, Hsu P, Tsai H, Lin Y, Chen K, Toh C, et al.
Sci Rep
. 2021 Dec;
11(1):24067.
PMID: 34911992
Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in glioblastoma. This Phase I study was initiated...
10.
Su P, Hsueh S, Tseng C, Ho M, Su P, Hung C, et al.
In Vivo
. 2021 Oct;
35(6):3391-3399.
PMID: 34697174
Background/aim: Cisplatin with 5-fluouracil (Cis/5Fu) and paclitaxel with carboplatin (Pac/Car) are common regimens used in concurrent chemoradiotherapy (CCRT) for patients with locally advanced esophageal cancer (EC). Here, we aimed to...